AbbVie Validates Voyager’s One-Shot Approach With Parkinson’s Collaboration
AbbVie and existing partner Voyager Therapeutics are attempting to cross the blood-brain barrier with a new collaboration on vectorized antibodies to treat Parkinson’s disease and other synucleinopathies such as Lewy body dementia and multiple system atrophy.
You may also be interested in...
The Japanese firm's original 2007 NDA was rejected in 2008 but it kept faith in the drug, now approved as an adjunct to levodopa/carbidopa. At least one competitor is waiting in the wings.
First quarter biopharma financing, at $17.96bn, demonstrated a 65% increase over Q4 2018. The $92bn in total M&A activity was led by Bristol-Myers Squibb's $74bn buy of top-tier public biotech Celgene. At $39.4bn in total potential deal value, alliance dealmaking started off 2019 strong, with most of the top partnerships in modalities outside the recently popular areas of immune checkpoint inhibitors or CAR-T therapies.
Novartis will take over development and commercialization of antisense candidate TQJ230 under rights it obtained in a 2017 agreement. Morphic and Janssen will collaborate on oral integrin inhibitors.